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Protein modification by ubiquitin has emerged as an
important cellular regulatory mechanism. Recent
studies illustrate the surprising ways in which
polyubiquitin chains are manipulated in the
regulation of NF-κB signaling.
Cells respond rapidly to changes in their internal and
external environments, often by using post-transla-
tional protein modifications to transmit signals from
the cell surface or internal sites to the nucleus. These
signaling pathways allow cells to respond to growth
signals, tolerate stresses or trigger programmed cell
death. In general, signaling pathway activation is
transient, with feedback mechanisms that reset the
regulatory network. Protein phosphorylation, for
example, is a well-characterized post-translational
mechanism for transmitting transient cellular signals
[1]. Phosphate groups, covalently attached to target
proteins by substrate-specific protein kinases, can
be removed by specific phosphatases, thereby ter-
minating the signaling cascade. Recent studies on
the NF-κB signaling network indicate that, in addition
to transient protein phosphorylation, polyubiquitin
chain attachment and removal work as on/off
switches at several points along the signal transduc-
tion pathways that lead to activation of NF-κB family
transcription factors.
The carboxyl terminus of the ubiquitin polypeptide
is enzymatically appended to lysines on target
proteins as well as on other ubiquitin molecules to
form polyubiquitin chains. Protein ubiquitination
involves the sequential action of ubiquitin-activating
enzyme (E1), ubiquitin-conjugating enzyme (E2) and
ubiquitin-protein ligase (E3) [2]. E3s bind both E2 and
substrate, and facilitate the transfer of ubiquitin mol-
ecules from the E2 to the substrate. Ubiquitin is best
known as a signal that targets proteins for degrada-
tion by the proteasome. In the ubiquitin–proteasome
pathway, proteins destined for degradation are
usually attached to a polyubiquitin chain in which
ubiquitin molecules are linked to one another by
amide bonds involving a specific ubiquitin lysine,
Lys48 [2]. Proteasomes recognize the Lys48-linked
chain, leading to degradation of the substrate and
recycling of the ubiquitin molecules. Ubiquitin
removal from proteins is catalyzed by a diverse group
of enzymes collectively termed deubiquitinating
enzymes.
Interplay of Ubiquitination and Phosphorylation in
NF-κB Regulation
As noted, protein phosphorylation and ubiquitination
are now both known to participate in the NF-κB sig-
naling pathway (Figure 1) [3]. NF-κB molecules can
concentrate in the nucleus and activate specific genes
only when inhibitory controls on NF-κB are relieved.
This occurs in response to DNA damage, during stim-
ulation by proinflammatory cytokines such as tumor
necrosis factor α (TNFα) or with an innate immunity
response initiated when a ligand interacts with a Toll-
like receptor (TLR) [4]. Mature NF-κB is normally kept
inactive by tight binding to an inhibitory protein called
IκB. Activation of NF-κB is triggered by site-specific
phosphorylation of IκB, which allows IκB to be recog-
nized by a ubiquitin-ligation complex. Polyubiquiti-
nated IκB is degraded by the proteasome, releasing
active NF-κB [3]. Regulation of NF-κB is thus directed
toward controlling cellular levels of IκB.
Remarkably, multiple studies now indicate that
polyubiquitin chain formation promotes protein–protein
associations that activate several steps in the signaling
cascades leading to activation of the IκB kinase (IKK)
complex [4]. These ubiquitin polymers are Lys63-linked
chains, rather than the Lys48-linked chains that target
proteins for proteasomal degradation. In the case of
TNFα stimulation (Figure 1), activated TNF receptor
recruits several adaptor proteins, including receptor-
interacting protein (RIP) and TNF receptor-associated
factor 2 (TRAF2). TNFα also induces polyubiquitination
of RIP (and TRAF2), allowing binding of TAB2, a regu-
latory subunit in the TAK1 kinase complex, and this
activates the TAK1 catalytic subunit [4] [5]. Active
TAK1 then phosphorylates, and thereby activates, IKK
(Figure 1).
A20 protein: A Dual-Function Ubiquitin Chain
Exchanger
The activation of IKK is transient, and recent findings
indicate that negative regulation of IKK depends on
specific deubiquitinating enzymes. This was first
demonstrated for the tumor suppressor CYLD [4,6].
Loss of CYLD leads to a disfiguring cancer syndrome
of the skin appendages called cylindromatosis. The
CYLD protein disassembles Lys63 polyubiquitin
chains on TRAF2 and the related TRAF6 protein.
Reduction of CYLD expression, or mutations that
abrogate its deubiquitinating activity, increase NF-κB
signaling, whereas CYLD overexpression has the
opposite effect.
Failure to attenuate the NF-κB signaling pathway
may lead to chronic inflammation and immune system
dysfunction. A human gene called A20, originally
identified by an mRNA that is strongly induced by
TNFα [7], encodes a key negative regulator of NF-κB
signaling. Studies in mice have shown that loss of A20
results in severe inflammation, cachexia and premature
death, and that fibroblasts derived from these mice are
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hypersensitive to TNFα and fail to downregulate NF-κB
[8]. The first hint that A20 function might be linked to
ubiquitin was the finding that it has an amino-terminal
‘ovarian tumor’ (OTU) domain. A20 and several other
OTU-related proteins were shown to have deubiquiti-
nating activity [4]. Therefore, a reasonable hypothesis
to explain how A20 downregulates NF-κB signaling
was that A20 removes the Lys63-polyubiquitin signal
from proteins such as TRAF6 or RIP.
Wertz et al. [9] have recently reported data that
support this idea, but also provide some unexpected
twists. They identified RIP as a target for A20 deubiq-
uitinating activity. This activity was traced to the OTU
domain, which preferentially removes Lys63-linked
ubiquitin chains from RIP. A20 with an active site
mutation in the OTU domain failed to turn down NF-κB
signaling in transfected cells from A20–/– mice. Sur-
prisingly, purified A20 was also shown to stimulate
ubiquitin chain formation in the presence of E1, E2
and ubiquitin. Not only was this E3 activity unantici-
pated, but A20 lacks any motifs that characterize the
majority of the known E3s [2]: the carboxy-terminal
half of A20 has seven zinc fingers, and the E3-like
activity was traced to the fourth of these (ZnF4).
Intriguingly, polyubiquitin chains synthesized by A20
are of the Lys48 variety. This suggested that A20
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Figure 1. Model for the roles of
ubiquitination and phosphorylation in
NF-κB activation.
The binding of a ligand to a plasma
membrane receptor, in this case TNFα to
TNFR1, causes trimerization of the
receptor and recruitment of the receptor-
associated proteins TRADD, RIP and the
ubiquitin ligase TRAF2, which is activated
as a result. Polyubiquitination of RIP (and
TRAF2) by Lys63-linked chains appears
to stimulate binding of the kinase
complex TAK1–TAB1–TAB2 to the mem-
brane-bound complex, thereby activating
the TAK1 kinase. TAK1 phosphorylates
the activation loop of the IKKβ subunit of
IKK, which in turn phosphorylates IκB.
This step is controlled by the NEMO
subunit of IKK which is also modified by
polyubiquitination. However, the mecha-
nistic effects of the NEMO modification
are not yet clear. Phosphorylated IκB is
modified with Lys48-linked polyubiquitin
chains by a specific ubiquitin-ligation
complex and is degraded by the protea-
some, allowing NF-κB to enter the
nucleus to turn on target genes.
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Figure 2. A sequential two-step
mechanism for downregulating TNFα
signaling by A20.
In this model, TNFα induces TRAF2-medi-
ated polyubiquitination of RIP. The Lys63
ubiquitin (Ub) chain on RIP is recognized
by TAB2, an adaptor subunit of the TAK1
kinase complex. Polyubiquitin binding to
TAB2–TAK1 activates TAK1 kinase activity
by an uncharacterized mechanism. TNFα
also increases A20 expression and the
association of A20 with RIP. The OTU
domain of A20 removes the Lys63-linked
ubiquitin chains from RIP, possibly disso-
ciating TAB2–TAK1, although this could
occur later. Deubiquitination of RIP is fol-
lowed by A20-ZnF-mediated modification
of RIP by Lys48-linked ubiquitin chains,
targeting RIP for proteasomal degradation.
Gold Ub ovals, Lys63-linked ubiquitin; cyan
Ub ovals, Lys48-linked ubiquitin.
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might stimulate the degradation of a positively acting
factor(s) in the NF-κB pathway.
RIP also turns out to be a key target of A20 E3
ligase activity. Wertz et al. [9] found that receptor-
associated RIP is ubiquitinated in an A20-dependent
manner in vivo and is degraded by the proteasome.
Direct ubiquitination of RIP by A20 was suggested by
in vitro assays, and ubiquitin ligase activity depended
on ZnF4 both in vivo and in vitro. Although it would at
first appear that the A20 polypeptide has opposing
enzyme activities, the distinct ubiquitin chains synthe-
sized or disassembled by the respective A20 domains
allow a way out of this paradox. In fact, the deubiqui-
tinating and E3 activities of A20 appear to function in
an ordered fashion: Lys63-linked ubiquitin chains on
RIP (attached by another ubiquitin ligase, possibly
TRAF2) are first removed by the OTU domain of A20
and this enables the ZnF to assemble a Lys48-linked
chain in its place (potentially on the same lysines)
(Figure 2). Kanayama et al. [5] recently demonstrated
that TAB2, the adaptor subunit of the TAK1 complex,
binds specifically to Lys63-linked ubiquitin chains on
RIP. This binding activates the TAK1 kinase. Thus, the
net effect of A20 on RIP is to exchange a Lys63 chain
necessary for signal transmission for a Lys48 chain
that targets RIP for destruction. In other words, both
A20 activities negatively regulate NF-κB signaling.
The function of A20 in NF-κB regulation goes beyond
the response to TNFα [10]. In mice lacking both A20
and TNFα, TLR-induced proinflammatory gene expres-
sion in macrophages persists abnormally, and the
mutant mice are highly susceptible to endotoxic shock.
This pathway is apparently independent of RIP.
Ubiquitin and Signal Transduction
The data of Wertz et al. [9] strongly imply that
modification of a protein with ubiquitin polymers of
different linkage has very different consequences [9].
To date, there is little evidence that chains of differ-
ent topology have different binding affinities to par-
ticular ubiquitin binding domains, although intact
TAB2 does prefer Lys63 over Lys48 chains [5]. This
preference is lost if the major ubiquitin binding
domain in TAB2 is expressed by itself. Perhaps mul-
tivalent interactions involving several ubiquitin
binding domains in a protein can confer greater
chain discrimination. Because proteasomes carry
tightly associated E3 ubiquitin-ligase as well as deu-
biquitinating enzyme subunits [11], another possibil-
ity is that the proteasomal E3(s) preferentially
extends Lys48 chains but not Lys63 ones or that the
deubiquitinating enzyme(s) preferentially cleaves
Lys63 chains. The net effect would be to enhance
degradation of Lys48-linked proteins while sparing
Lys63-linked ones.
Removal of Lys63-ubiquitin chains from RIP by
A20 is insufficient to downregulate TNFα signaling;
signal attenuation also seems to require that A20
synthesize a Lys48-ubiquitin chain on RIP [9]. It is
known that proteasomes have a sophisticated
‘unfoldase’ activity that can pluck individual subunits
from a multisubunit complex and degrade them
selectively [12]. Lys48-polyubiquitin-modified RIP
might be subject to this activity. In this view, Lys63-
linked chains facilitate activated complex assembly
but Lys48-linked chains trigger proteasome-medi-
ated disassembly (and usually degradation). These
ubiquitin chain-dependent mechanisms might be
crucial for controlling the duration and strength of
signaling in the NF-κB pathway and perhaps other
signaling pathways.
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